Investigational therapies in the treatment of obesity

Bibliography

• BRAY GA: Medical consequences of obesity. J. Clin. Endocrinol. Metab. (2004) 89(6):2583-2589.
   PubMed Web of Science ®Google Scholar
• KOPELMAN PG: Obesity as a medical problem. Nature (2000) 404:635-643.
   PubMed Web of Science ®Google Scholar
• KALRA SP, DUBE MG, PU S et al.: Interacting appetite-regulating pathways in the hypothalamic regulation of body weight. Endocr. Rev. (1999) 20:68-100.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ MW, WOODS SC, PORTE D JR et al.: Central nervous system control of food intake. Nature (2000) 404:661-671.
   PubMed Web of Science ®Google Scholar
• ZIGMAN JM, ELMQUIST JK: From anorexia to obesity – the yin and yang of body weight control. Endocrinology (2003) 144(9):3749-3756.
   PubMed Web of Science ®Google Scholar
• HALPERN A, MANCINI MC: Treatment of obesity: an update on antiobesity medications. Obes. Rev. (2002) 4:25-42.
   Google Scholar
• CONNOLLY HM, McGOON MD: Obesity drugs and the heart. Curr. Probl. Cardiol. (1999) 12:745-92.
   Google Scholar
• MAFFEI M, HALAAS J, RAVUSSIN E et al.: Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat. Med. (1995) 1(11):1155-1161.
   PubMed Web of Science ®Google Scholar
• PELLEYMOUNTER MA, CULLEN MJ, BAKER MB et al.: Effects of the obese gene product on body weight regulation in ob/ob mice. Science (1995) 269(5223):540-543.
   PubMed Web of Science ®Google Scholar
• HALAAS JL, GAJIWALA KS, MAFFEI M et al.: Weight-reducing effects of the plasma protein encoded by the obese gene. Science (1995) 269(5223):543-546.
   PubMed Web of Science ®Google Scholar
• CAMPFIELD LA, GUISEZ Y, DEVOS R et al.: Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks. Science (1995) 269(5223):546-549.
   PubMed Web of Science ®Google Scholar
• LEVIN N, NELSON C, GURNEY A et al.: Decreased food intake does not completely account for adiposity reduction after ob protein infusion. Proc. Natl. Acad. Sci. USA (1996) 93(4):1726-1730.
   PubMed Web of Science ®Google Scholar
• EMILSON V, LIU YL, CAWTHORNE MA et al.: Expression of the functional leptin receptor mRNA in pancreatic islets and direct inhibitory action of leptin on insulin secretion. Diabetes (1997) 46(2):313-316.
   PubMed Web of Science ®Google Scholar
• SHIMABUKURO M, KOYAMA K, LEE Y et al.: Leptin- or troglitazone-induced lipopenia protects islets from interleukin 1β cytotoxicity. J. Clin. Invest. (1997) 100(7):1750-4.
   PubMed Web of Science ®Google Scholar
• SHIMABUKURO M, KOYAMA K, CHEN G et al.: Direct antidiabetic effect of leptin through triglyceride depletion of tissues. Proc. Natl. Acad. Sci. USA (1997) 94(9):4637-41.
   PubMed Web of Science ®Google Scholar
• CHEN H, CHARLAT O, TARTAGLIA LA et al.: Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Cell (1996) 84(3):491-495.
   PubMed Web of Science ®Google Scholar
• TARTAGLIA LA, DEMBSKI M, WENG X et al.: Identification and expression cloning of a leptin receptor, OB-R. Cell (1995) 83(7):1263-1271.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ MW, SEELEY RJ, CAMPFIELD LA et al.: Identification of targets of leptin action in rat hypothalamus. J. Clin. Invest. (1996) 98(5):1101-1106.
   PubMed Web of Science ®Google Scholar
• LEBEL C, BOURDEAU A, LAU D et al.: Biologic response to peripheral and central administration of recombinant human leptin in dogs. Obes. Res. (1999) 7(6):577-585.
   PubMedGoogle Scholar
• HEYMSFIELD SB, GREENBERG AS, FUJIOKA K et al.: Recombinant leptin for weight loss in obese and lean adults: a randomised, controlled, dose-escalation trial. J. Am. Med. Assoc. (1999) 282(16):1568-1575.
   PubMed Web of Science ®Google Scholar
• CHINOOKOSWONG N, KORACH E, LEBEL C et al.: Additive effects of leptin and oral anti-obesity drugs in treating diet-induced obesity in rats. Diabetes (2002) 51:2.
   Google Scholar
• BOOZER CN, LEIBEL RL, LOVE RJ et al.: Synergy of sibutramine and low-dose leptin in treatment of diet-induced obesity in rats. Metabolism (2001) 50(8):889-893.
   PubMed Web of Science ®Google Scholar
• FAROOQI IS, JEBB AS, LANGMARCK G et al.: Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N. Engl. J. Med. (1999) 341(12):879-884.
   PubMed Web of Science ®Google Scholar
• GIBSON WT, FAROOQI IS, MOREAU M et al.: Congenital leptin deficiency due to homozygosity for the Δ133G mutation: report of another case and evaluation of response to four years of leptin therapy. J. Clin. Endocrinol. Metab. (2004) 89(10):4821-4826.
   PubMed Web of Science ®Google Scholar
• McDUFFIE JR, RIGGS PA, CARIS KA et al.: Satiety and satiation in patients with lipodystrophy and leptin insufficiency. J. Clin. Endocrinol. Metab. (2004) 89(9):4258-4263.
   PubMed Web of Science ®Google Scholar
• HOLLANDER P, LEWIS GF, SCHWARTZ S et al.: A randomised double-blind placebo controlled study to determine the effects of subcutaneous (SC) recombinant methionyl human leptin (A-100) on glycemic control in obese subjects with diet treated Type 2 diabetes mellitus (DM). Diabetes (2000) 49(Suppl. 1).
   PubMedGoogle Scholar
• MANEUF Y, HIGGINBOTTOM M, PRITCHARD M et al.: Small molecule leptin mimetics overcome leptin resistance in obese rats. Funda,. Clin. Pharmacol. (2004) 18(Suppl. 1):83.
   Google Scholar
• HOFBAUER KG: Molecular pathways to obesity. Int. J. Obes. Relat. Metab. Disord. (2002) 26(Suppl. 2):S18-S27.
   PubMedGoogle Scholar
• LO K-M, ZHANG J, SUN Y et al.: Engineering a pharmacologically superior form of leptin for the treatment of obesity. Protein Eng. Des. Sel. (2005) 18(1):1-10.
   PubMed Web of Science ®Google Scholar
• FOSTER AC, JOPPA M, MARKISON S et al.: Body weight regulation by selective MC4 receptor agonists and antagonists. Ann. NY Acad. Sci. (2003) 994:103-110.
   PubMed Web of Science ®Google Scholar
• KOEGLER FH, GROVE KL, SCHIFFMACHER A et al.: Central melanocortin receptors mediate changes in food intake in the rhesus macaque. Endocrinology (2001) 142(6):2586-2592.
   PubMed Web of Science ®Google Scholar
• JONSSON L, SKARPHEDINSSON JO, SKULADOTTIR GV et al.: Food conversion is transiently affected during 4-week chronic administration of melanocortin agonist and antagonist in rats. J. Endocrinol. (2002) 173(3):517-523.
   PubMedGoogle Scholar
• BENOIT SC, SCHWARTZ MW, LACHEY JL et al.: A novel selective melanocortin-4 receptor agonist reduces food intake in rats and mice without producing aversive consequences. J. Neurosci. (2000) 20(9):3442-3448.
   PubMed Web of Science ®Google Scholar
• CHEUNG AW, DANHO W, SWISTOK J et al.: Structure–activity relationship of linear peptide Bu-His-dPhe-Arg-Trp-Gly-NH2 at the human melanocortin-1 and -4 receptors: arginine substitution. Bioorg. Med. Chem. Lett. (2002) 12(17):2407-2410.
   PubMed Web of Science ®Google Scholar
• CHEUNG AW, DANHO W, SWISTOK J et al.: Structure–activity relationship of linear peptide Bu-His-dPhe-Arg-Trp-Gly-NH2 at the human melanocortin-1 and -4 receptors: histidine substitution. Bioorg. Med. Chem. Lett. (2003) 13(1):133-137.
   PubMed Web of Science ®Google Scholar
• DANHO W, SWISTOK J, CHEUNG AW et al.: Structure–activity relationship of linear peptide Bu-His-dPhe-Arg-Trp-Gly-NH2 at the human melanocortin-1 and -4 receptors: dPhe and Trp substitution. Bioorg. Med. Chem. Lett. (2003) 13(4):649-652.
   PubMed Web of Science ®Google Scholar
• BANNO R, ARIMA H, SATO I et al.: The melanocortin agonist melanotan II increases insulin sensitivity in OLETF rats. Peptides (2004) 25(8):1279-1286.
   PubMed Web of Science ®Google Scholar
• HEIJBOER AC, VAN DEN HOEK AM, PIJL H et al.: Intracerebroventricular administration of melanotan II increases insulin sensitivity of glucose disposal in mice. Diabetologia (2005) 48(8):1621-1626.
   PubMed Web of Science ®Google Scholar
• BEDNAREK MA, MacNEIL T, TANG R et al.: Potent and selective peptide agonists of α-melanotropin action at human melanocortin receptor 4: their synthesis and biological evaluation in vitro. Biochem. Biophys. Res. Commun. (2001) 286(3):641-645.
   PubMed Web of Science ®Google Scholar
• PONTILLO J, TRAN JA, ARELLANO M et al.: Structure–activity relationships of piperazinebenzylamines as potent and selective agonists of the human melanocortin-4 receptor. Bioorg. Med. Chem. Lett. (2004) 14(17):4417-4423.
   PubMed Web of Science ®Google Scholar
• TRAN JA, PONTILLO J, ARELLANO M et al.: Identification of agonists and antagonists of the human melanocortin-4 receptor from piperazinebenzylamines. Bioorg. Med. Chem. Lett. (2005) 15(3):833-837.
   PubMed Web of Science ®Google Scholar
• DYCK B, PARKER J, PHILLIPS T et al.: Aryl piperazine melanocortin MC4 receptor agonists. Bioorg. Med. Chem. Lett. (2003) 13(21):3793-3796.
   PubMed Web of Science ®Google Scholar
• ARASASINGHAM PN, FOTSCH C, OUYANG X et al.: Structure–activity relationship of (1-aryl-2-piperazinylethyl)- piperazines: antagonists for the AGRP/melanocortin receptor binding. J. Med. Chem. (2003) 46(1):9-11.
   PubMed Web of Science ®Google Scholar
• FOTSCH C, HAN N, ARASASINGHAM P et al.: Melanocortin subtype-4 receptor agonists containing a piperazine core with substituted aryl sulfonamides. Bioorg. Med. Chem. Lett. (2005) 15(6):1623-1627.
   PubMed Web of Science ®Google Scholar
• YE Z, GUO L, BARAKAT KJ et al.: Discovery and activity of (1R,4S,6R)-N-[(1R)-2-[4-cyclohexyl-4- [[(1,1-dimethylethyl)amino]carbonyl]-1- piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-2-methyl-2-azabicyclo[2.2.2]- octane-6-carboxamide (3, RY764), a potent and selective melanocortin subtype-4 receptor agonist. Bioorg. Med. Chem. Lett. (2005) 15(15):3501-3505.
   PubMed Web of Science ®Google Scholar
• FOTSCH C, SMITH DM, ADAMS JA et al.: Design of a new peptidomimetic agonist for the melanocortin receptors based on the solution structure of the peptide ligand, Ac-Nle-cyclo[Asp-Pro-DPhe-Arg-Trp-Lys]- NH2. Bioorg. Med. Chem. Lett. (2003) 13(14):2337-2340.
   PubMed Web of Science ®Google Scholar
• GRIECO P, BALSE-SRINIVASAN P, HAN G et al.: Extensive structure-activity studies of lactam derivatives of MT-II and SHU-9119: their activity and selectivity at human melanocortin receptors 3, 4, and 5. J. Pept. Res. (2003) 62(5):199-206.
   PubMedGoogle Scholar
• CEPOI D, PHILLIPS T, CISMOWSKI M et al.: Assessment of a small molecule melanocortin-4 receptor-specific agonist on energy homeostasis. Brain Res. (2004) 1000(1):64-71.
   PubMed Web of Science ®Google Scholar
• NICKOLLS SA, FLECK B, HOARE SRJ et al.: Functional selectivity of melanocortin-4 receptor peptide and nonpeptide agonists: evidence for ligand-specific conformational states. J. Pharmacol. Exp. Ther. (2005) 313(3):1281-1288.
   PubMed Web of Science ®Google Scholar
• BLUNDELL JE: Is there a role for serotonin (5-hydroxytryptamine) in feeding? Int. J. Obes. (1977) 1(1):15-42.
   PubMed Web of Science ®Google Scholar
• GREENO CG, WING RR: A double-blind, placebo-controlled trial of the effect of fluoxetine on dietary intake in overweight women with and without binge-eating disorder. Am. J. Clin. Nutr. (1996) 64(3):267-273.
   PubMed Web of Science ®Google Scholar
• CONNOLLY HM, CRARY JL, McGOON MD et al.: Valvular heart disease associated with fenfluramine–phentermine. N. Engl. J. Med. (1997) 337:581-588.
   PubMed Web of Science ®Google Scholar
• BARNES NM, SHARP T: A review of central 5-HT receptors and their function. Neuropharmacology (1999) 38:1083-1152.
   PubMed Web of Science ®Google Scholar
• TECOTT LH, SUN LM, AKANA SF et al.: Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors. Nature (1995) 374(6522):542-546.
   PubMed Web of Science ®Google Scholar
• NONOGAKI K, STRACK AM, DALLMAN MF et al.: Leptin-independent hyperphagia and Type 2 diabetes in mice with a mutated serotonin 5-HT2C receptor gene. Nat. Med. (1998) 4(10):1152-1156.
   PubMed Web of Science ®Google Scholar
• HALFORD JCG, WANNINAYAKE SCD, BLUNDELL JE: Behavioural satiety sequence (BSS) for the diagnosis of drug action on food intake. Pharmacol. Biochem. Behav. (1998) 61:159-168.
   PubMed Web of Science ®Google Scholar
• WALSH AE, SMITH KA, OLDMAN AD: m-Chlorophenyl-piperazine decreases food intake in a test meal. Psychopharmacology (1994) 116:120-122.
   PubMed Web of Science ®Google Scholar
• SARGENT PA, SHARPLEY AL, WILLIAMS C: 5-HT2C activation decreases appetite and body weight in obese subjects. Psychopharmacology (1997) 133:309-312.
   PubMed Web of Science ®Google Scholar
• BOELES S, WILLIAMS C, CAMPLING GM: Sumatriptan decreases food intake and increases plasma growth hormone in women. Psychopharmacology (1997) 129:179-182.
   PubMed Web of Science ®Google Scholar
• DUNLOP J, SABB AL, MAZANDARANI H et al.: WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi] indole], a novel 5-hydroxytryptamine 2C receptor-selective agonist with anorectic activity. J. Pharmacol. Exp. Ther. (2005) 313(2):862-869.
   PubMed Web of Science ®Google Scholar
• SMITH BM, SMITH JM, TSAI JH et al.: Discovery and SAR of new benzanepines as potent and selective 5-HT2C receptor agonists for the treatment of obesity. Bioorg. Med. Chem. Lett. (2005) 15(5):1467-1470.
   PubMed Web of Science ®Google Scholar
• JANDACEK RJ: APD-356 (Arena). Curr. Opin. Investig. Drugs (2005) 6(10):1051-1056.
   PubMedGoogle Scholar
• ENNIS MD, HOFFMAN RL, GHAZAL NB et al.: 2,3,4,5-tetrahydro- and 2,3,4,5,11,11a-hexahydro-1H-[1,4]diazepino[1,7-a]indoles: new templates for 5-HT2C agonists. Bioorg. Med. Chem. Lett. (2003) 13(14):2369-2372.
   PubMed Web of Science ®Google Scholar
• FELICINI C, FONTANA E, GIRIBONE D et al.: Synthesis of PNU-243922 labeled with 14C. J. Labelled Comp. Radiopharm. (2003) 46(1):85-92.
   Web of Science ®Google Scholar
• WELMAKER GS, NELSON JA, SABALSKI JE et al.: Synthesis and 5-hydroxytryptamine (5-HT) activity of 2,3,4,4a-tetrahydro-1H-pyrazino[1,2-a] quinoxalin-5-(6H)ones and 2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2-a]quinoxalines. Bioorg. Med. Chem. Lett. (2000) 10(17):1991-1994.
   PubMed Web of Science ®Google Scholar
• XU J: Metabolic Diseases Drug Discovery World Summit – SRI Conference. Diabetes and Obesity. IDrugs (2003) 6(9):850-851.
   PubMed Web of Science ®Google Scholar
• MAZUCCO RA, OGNJENOVIC M: American Chemical Society – 225th National Meeting, New Orleans, USA. IDrugs (2003) 6(5):403-416.
   PubMed Web of Science ®Google Scholar
• LUO S, MEIER AH, CINCOTTA AH: Bromocriptine reduces obesity, glucose intolerance and extracellular monoamine metabolite levels in the ventromedial hypothalamus of Syrian hamsters. Neuroendocrinology (1998) 68:1-10.
   PubMed Web of Science ®Google Scholar
• LUO S, LUO J, MEIER AH et al.: Dopaminergic neurotoxin administration to the area of the suprachiasmatic nuclei induces insulin resistance. Neuroreport (1997) 8:3495-3499
   PubMed Web of Science ®Google Scholar
• SCISLOWSKI PW, TOZZO E, ZHANG Y et al.: Biochemical mechanisms responsible for the attenuation of diabetic and obese conditions in ob/ob mice treated with dopaminergic agonists. Int. J. Obes. Relat. Metab. Disord. (1999) 23:425-431.
   PubMed Web of Science ®Google Scholar
• KAMATH V, JONES CN, YIP JC et al.: Effects of a quick-release form of bromocriptine (Ergoset) on fasting and postprandial plasma glucose, insulin, lipid, and lipoprotein concentrations in obese nondiabetic hyperinsulinemic women. Diabetes Care (1997) 20:1697-1701.
   PubMed Web of Science ®Google Scholar
• PIJL H, OHASHI S, MATSUDA M et al.: Bromocriptine: a novel approach to the treatment of Type 2 diabetes. Diabetes Care (2000) 23(8):1154-1161.
   PubMed Web of Science ®Google Scholar
• GADDE KM, PARKER CB, MANER LG et al.: Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women. Obes. Res. (2001) 9(9):544-551.
   PubMedGoogle Scholar
• ANDERSON JW, GREENWAY FL, FUJIOKA K et al.: Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial. Obes. Res. (2002) 10(7):633-641.
   PubMedGoogle Scholar
• JAIN AK, KAPLAN RA, GADDE KM et al.: Bupropion SR versus placebo for weight loss in obese patients with depressive symptoms. Obes. Res. (2002) 10(10):1049-1056.
   PubMedGoogle Scholar
• BOTELLA-CARRETERO JI, ESCOBAR-MORREALE HF, MARTIN I et al.: Weight gain and cardiovascular risk factors during smoking cessation with bupropion or nicotine. Horm. Metab. Res. (2004) 36(3):178-182.
   PubMed Web of Science ®Google Scholar
• VOLKOW ND, WANG GJ, FOWLER JS et al.: The slow and long-lasting blockade of dopamine transporters in human brain induced by the new antidepressant drug radafaxine predict poor reinforcing effects. Biol. Psychiatry (2005) 57(6):640-646.
   PubMed Web of Science ®Google Scholar
• OKADA M, KANEKO S, HIRANO T et al.: Effects of zonisamide on dopaminergic system. Epilepsy Res. (1995) 22(3):193-205.
   PubMed Web of Science ®Google Scholar
• OKADA M, HIRANO T, KAWATA Y et al.: Biphasic effects of zonisamide on serotonergic system in rat hyppocampus. Epilepsy Res. (1999) 34(2):187-197.
   PubMed Web of Science ®Google Scholar
• GADDE KM, FRANCISCY DM, WAGNER R II, KRISHNAN RR: Zonisamide for weight loss in obese adults. J. Am. Med. Assoc. (2003) 289:1820-1825.
   PubMed Web of Science ®Google Scholar
• SHADID S, JENSEN MD: Effects of growth hormone administration in human obesity. Obes. Res. (2003) 11(2):170-175.
   PubMedGoogle Scholar
• OGRU E, WILSON JC, HEFFERNAN M et al.: The conformational and biological analysis of a cyclic anti-obesity peptide from the C-terminal domain of human growth hormone. J. Pept. Res. (2000) 56(6):388-397.
   PubMedGoogle Scholar
• HEFFERNAN M, SUMMERS RJ, THORBURN A et al.: The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and β3-AR knock-out mice. Endocrinology (2001) 142(12):5182-5189.
   PubMed Web of Science ®Google Scholar
• HEFFERNAN MA, THORBURN AW, FAM B et al.: Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. Int. J. Obes. Relat. Metab. Disord. (2001) 25(10):1442-1449.
   PubMed Web of Science ®Google Scholar
• NG FM, SUN J, SHARMA L et al.: Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm. Res. (2000) 53(6):274-278.
   PubMed Web of Science ®Google Scholar
• LITTLE TJ, HOROWITZ M, FEINLE-BISSET C: Role of cholecystokinin in appetite control and body weight regulation. Obes. Rev. (2005) 6(4):297-306.
   PubMed Web of Science ®Google Scholar
• BIGNON E, BACHY A, BOIGEGRAIN R et al.: SR146131: a new potent, orally active, and selective nonpeptide cholecystokinin subtype 1 receptor agonist – in vivo pharmacological characterization. J. Pharmacol. Exp. Ther. (1999) 289(2):752-761.
   PubMed Web of Science ®Google Scholar
• KORNER J, LEIBEL RL: To eat or not to eat: how the gut talks to the brain. N. Engl. J. Med. (2003) 349(10):926-928.
   PubMed Web of Science ®Google Scholar
• EBERLEIN GA, EYSSELEIN VE, SCHAEFFER M et al.: A new molecular form of PYY: structural characterization of human PYY3-36 and PYY1-36. Peptides (1989) 10:797-803.
   PubMed Web of Science ®Google Scholar
• BATTERHAM RL, COHEN MA, ELLIS SM et al.: Inhibition of food intake in obese subjects by peptide YY3-36. N. Engl. J. Med. (2003) 349(10):941-948.
   PubMed Web of Science ®Google Scholar
• KOEGLER FH, ENRIORI PJ, BILLES SK et al.: Peptide YY3-36 inhibits morning, but not evening, food intake and decreases body weight in Rhesus macaques. Diabetes (2005) 54(11):3198-3204.
   PubMed Web of Science ®Google Scholar
• SILENO AP, BRANDT GC, SPANN BM et al.: Lower mean weight after 14 days intravenous administration peptide YY3–36 (PYY3-36) in rabbits. Int. J. Obes. Relat. Metab. Dis. (2005) (In Press).
   Google Scholar
• PARK A, WYNNE K, SILENO A et al.: Nasal peptide YY3-36: Phase I dose ranging and safety study in healthy human subjects. 13th European Congress on Obesity, Prague, Czech Republic (26 – 29 May 2004) (Abstract).
   Google Scholar
• WYNNE K, STANLEY S, BLOOM S: The gut and regulation of body weight. J. Clin. Endocrinol. Metab. (2004) 89(6):2576-2582.
   PubMed Web of Science ®Google Scholar
• COHEN MA, ELLIS SM, LE ROUX CW et al.: Oxyntomodulin suppresses appetite and reduces food intake in humans. J. Clin. Endocrinol. Metab. (2003) 88:4696-4701.
   PubMed Web of Science ®Google Scholar
• DAKIN CL, SMALL CJ, BATTERHAM RL et al.: Peripheral oxyntomodulin reduces food intake and body weight gain in rats. Endocrinology (2004) 145:2687-2695.
   PubMed Web of Science ®Google Scholar
• WYNNE K, PARK AJ, SMALL CJ et al.: Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial. Diabetes (2005) 54(8):2390-2395.
   PubMed Web of Science ®Google Scholar
• PETERSON WM, WANG Q, TZEKOVA R et al.: Ciliary neurotrophic factor and stress stimuli activate the Jak-STAT pathway in retinal neurons and glia. J. Neurosci. (2000) 20(11):4081-4090.
   PubMed Web of Science ®Google Scholar
• PANAYOTATOS N, RADZIEJEWSKA E, ACHESON A et al.: Exchange of a single amino acid interconverts the specific activity and gel mobility of human and rat ciliary neurotrophic factors. J. Biol. Chem. (1993) 268(25):19000-19003.
   PubMed Web of Science ®Google Scholar
• AMYOTROPHIC LATERALSCLEROSIS CNTF TREATMENT STUDY GROUP: A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. Neurology (1996) 46:1244-1249.
   PubMed Web of Science ®Google Scholar
• IP NY, NYE SH, BOULTON TG et al.: CNTF and LIF act on neuronal cells via shared signaling pathways that involve the IL-6 signal transducing receptor component gp130. Cell (1992) 69(7):1121-1132.
   PubMed Web of Science ®Google Scholar
• DAVIS S, ALDRICH TH, VALENZUELA DM et al.: The receptor for ciliary neurotrophic factor. Science (1991) 253(5015):59-63.
   PubMed Web of Science ®Google Scholar
• MARSH DJ, HOLLOPETER G, HUSZAR D et al.: Response of melanocortin-4 receptor-deficient mice to anorectic and orexigenic peptides. Nat. Genet. (1999) 21(1):119-122.
   PubMed Web of Science ®Google Scholar
• GLOAGUEN I, COSTA P, DEMARTIS A et al.: Ciliary neurotrophic factor corrects obesity and diabetes associated with leptin deficiency and resistance. Proc. Natl. Acad. Sci. USA (1997) 94(12):6456-6461.
   PubMed Web of Science ®Google Scholar
• ANDERSON KD, LAMBERT PD, CORCORAN TL et al.: Activation of the hypothalamic arcuate nucleus predicts the anorectic actions of ciliary neurotrophic factor and leptin in intact and gold thioglucose-lesioned mice. J. Neuroendocrinol. (2003) 15(7):649-660.
   PubMed Web of Science ®Google Scholar
• BLUHER S, MOSCHOS S, BULLEN J Jr et al.: Ciliary neurotrophic factor Ax15 alters energy homeostasis, decreases body weight, and improves metabolic control in diet-induced obese and UCP1-DTA mice. Diabetes (2004) 53(11):2787-2796.
   PubMed Web of Science ®Google Scholar
• ETTINGER MP, LITTLEJOHN TW, SCHWARTZ SL et al.: Recombinant variant of ciliary neurotrophic factor for weight loss in obese adults: a randomized, dose-ranging study. J. Am. Med. Assoc. (2003) 289(14):1826-1832.
   PubMed Web of Science ®Google Scholar
• WATT MJ, HEVENER A, LANCASTER GI, FEBBRAIO MA: Ciliary neurotrophic factor prevents acute lipid-induced insulin resistance by attenuating ceramide accumulation and phosphorylation of JNK in peripheral tissues. Endocrinology (2006) (In Press).
   Google Scholar
• TATARANNI PA, PRATLEY R, SHULDINER A et al.: β3-adrenergic receptor gene variant and lipid metabolism in Pima Indians. Diabetologia (1997) 40(1):123-124.
   PubMedGoogle Scholar
• WALSTON J, SILVER K, BOGARDUS C et al.: Time of onset of non-insulin-dependent diabetes mellitus and genetic variation in the β3-adrenergic-receptor gene. N. Engl. J. Med. (1995) 333(6):343-347.
   PubMed Web of Science ®Google Scholar
• CONNOLEY IP, LIU YL, FROST I et al.: Thermogenic effects of sibutramine and its metabolites. Br. J. Pharmacol. (1999) 126(6):1487-1495.
   PubMed Web of Science ®Google Scholar
• UKKOLA O, RAVUSSIN E, JACOBSON P et al.: Mutations in the adiponectin gene in lean and obese subjects from the Swedish obese subjects cohort. Metabolism (2003) 52(7):881-884.
   PubMed Web of Science ®Google Scholar
• DIEZ JJ, IGLESIAS P: The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur. J. Endocrinol. (2003) 148(3):293-300.
   PubMed Web of Science ®Google Scholar
• TSAO TS, LODISH HF, FRUEBIS J: ACRP30, a new hormone controlling fat and glucose metabolism. Eur. J. Pharmacol. (2002) 440(2-3):213-221.
   PubMed Web of Science ®Google Scholar
• YAMAUCHI T, KAMON J, ITO Y et al.: Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature (2003) 423(6941):762-769 [Erratum in: Nature (2004) 431(7012):1123].
   PubMed Web of Science ®Google Scholar
• FRUEBIS J: Proteolytic cleavage product of 30-kDa adipocyte-complement related protein increases fatty-acid oxidation in muscle and causes weight loss in mice. Proc. Natl. Acad. Sci. USA (2001) 98(4):2005-2010.
   PubMed Web of Science ®Google Scholar
• SHKLYAEV S, ASLANIDI G, TENNANI M et al.: Sustained peripheral expression of transgene adiponectin offsets the development of diet-induced obesity in rats. Proc. Natl. Acad. Sci. USA (2003) 100(24):14217-14222.
   PubMed Web of Science ®Google Scholar
• HOLST JJ: Glucagon-like peptide-1: physiology and therapeutical potential. Curr. Opin. Endocrinol. Diabetes (2005) 12:52-62.
   Google Scholar
• FLINT A, RABEN A, ASTRUP A et al.: Glucagon-like peptide-1 promotes satiety and supresses energy intake in humans. J. Clin. Invest. (1998) 101:515-520.
   PubMed Web of Science ®Google Scholar
• GUTZWILLER JP, KE B, DREWE J et al.: Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut (1999) 44:81-86.
   PubMed Web of Science ®Google Scholar
• TURTON MD, O’SHEA D, GUNN I et al.: A role for glucagon-like peptide-1 in the central regulation of feeding. Nature (1996) 379:69-72.
   PubMed Web of Science ®Google Scholar
• GOKE R, FEHMANN HC, LINN T et al.: Exendin-4 is a high potency agonist and truncated exendin(9-39)-amide an antagonist at the glucagon-like peptide-1-(7-36)-amide receptor of insulin-secreting β cells. J. Biol. Chem. (1993) 268:19650-19655.
   PubMed Web of Science ®Google Scholar
• EDWARDS CM, STANLEY AS, DAVIS R et al.: Exendin-4 reduces fasting and post-prandial glucose and decreases energy intake in healthy volunteers. Am. J. Physiol. Endocrinol. Metab. (2001) 281:E155-E161.
   PubMed Web of Science ®Google Scholar
• HARDER H, NIELSEN L, THI TDT, ASTRUP A: The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with Type 2 diabetes. Diabetes Care (2004) 27:1915-1921.
   PubMed Web of Science ®Google Scholar
• MADSBAD S, SCHMITZ O, RANSTAM J et al.: Improved glycemic control with no weight increase in patients with Type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211). Diabetes Care (2004) 27:1335-1342.
   PubMed Web of Science ®Google Scholar
• NAUCK M, HOMPESCH M, FILIPCZAK R et al.: Liraglutide as add-on to metformin in Type 2 diabetes: a significant improvement in glycaemic control with a reduction in body weight compared with glimepiride [abstract]. Diabetologia (2004) 47(Suppl. 1):A281.
   Google Scholar
• DIEHL AM, HOEK JB: Mitochondrial uncoupling: role of uncoupling protein anion carries and relationship to thermogenesis and weight control. ‘The benefits of losing control’. J. Bioenerg. Biomembr. (1999) 31(5):494-506.
   Web of Science ®Google Scholar
• VIDAL-PUIG AJ, GRUJIC D, ZHANG C-Y et al.: Energy metabolism in uncoupling protein 3 gene knock-out mice. J. Biol. Chem. (2000) 275(21):16258-16266.
   PubMed Web of Science ®Google Scholar
• NEDERGAARD J, GOLOZOUBOVA V, MATTHIAS A et al.: Life without UCP1: mithocondrial cellular and organismal characteristics of the UCP1-ablated mice. Biochem. Soc. Trans. (2001) 29(Part 6):756-763.
   PubMed Web of Science ®Google Scholar
• HORVATH TL, CASTANEDA T, TANG-CHRISTENSEN M et al.: Ghrelin as a potential anti-obesity target. Curr. Pharm. Des. (2003) 9(17):1383-1395.
   PubMed Web of Science ®Google Scholar
• POPOVIC V, DUNTAS LH: Brain somatic cross-talk: ghrelin, leptin and ultimate challengers of obesity. Nutr. Neurosci. (2005) 8(1):1-5.
   PubMed Web of Science ®Google Scholar
• HOLST B, CYGANKIEWICZ A, JENSEN TH et al.: High constitutive signaling of the ghrelin receptor – identification of a potent inverse agonist. Mol. Endocrinol. (2003) 17(11):2201-2210.
   PubMed Web of Science ®Google Scholar
• ZHAO H, XIN Z, LIU G et al.: Discovery of tetralin carboxamide growth hormone secretagogue receptor antagonists via scaffold manipulation. J. Med. Chem. (2004) 47(27):6655-6657.
   PubMed Web of Science ®Google Scholar
• ASAKAWA A, INUI A, KAGA T et al.: Antagonism of ghrelin receptor reduces food intake and body weight gain in mice. Gut (2003) 52(7):947-952.
   PubMed Web of Science ®Google Scholar
• BECK B, RICHY S, STRICKER-KRONGRAD A: Feeding response to ghrelin agonist and antagonist in lean and obese Zucker rats. Life Sci. (2004) 76(4):473-478.
   PubMed Web of Science ®Google Scholar
• HALEM HA, TAYLOR JE, DONG JZ et al.: A novel growth hormone secretagogue-1a receptor antagonist that blocks ghrelin-induced growth hormone secretion but induces body weight gain. Neuroendocrinol. (2005) 81(5):339-349.
   PubMed Web of Science ®Google Scholar
• NORMAN MH, CHEN N, CHEN Z et al.: Structure-activity relationships of a series of pyrrolo[3,2-d]pyrimidine derivatives and related compounds as neuropeptide Y5 receptor antagonists. J. Med. Chem. (2000) 43(22):4288-4312.
   PubMed Web of Science ®Google Scholar
• BALASUBRAMANIAM A, SHERIFF S, JOHNSON ME et al.: (D-TRP32]neuropeptide Y: a competitive antagonist of NPY in rat hypothalamus. J. Med. Chem. (1994) 37(6):811-815.
   PubMed Web of Science ®Google Scholar
• KUSHI A, SASAI H, KOIZUMI H et al.: Obesity and mild hyperinsulinemia found in neuropeptide Y-Y1 receptor-deficient mice. Proc. Natl. Acad. Sci. USA (1998) 95(26):15659-15664.
   PubMed Web of Science ®Google Scholar
• ISHIHARA A, TANAKA T, KANATANI A et al.: A potent neuropeptide Y antagonist, 1229U91, supressed spontaneous food intake in Zucker fatty rats. Am. J. Physiol. (1998) 274(5 Part 2):R1500-R1504.
   PubMed Web of Science ®Google Scholar
• BECK B, STRICKER-KRONGRAD A, MUSSE N et al.: Putative neuropeptide Y antagonist failed to decrease overeating in obese Zucker rats. Neurosci. Lett. (2004) 181(1-2):126-128.
   Google Scholar
• KANATANI A, KANNO T, ISHIHARA A et al.: The novel neuropeptide Y Y1 receptor antagonist J-104870: a potent feeding suppressant with oral bioavailability. Biochem. Biophys. Res. Commun. (1999) 266(1):88-91.
   PubMed Web of Science ®Google Scholar
• KANATANI A, HATA M, MASHIKO S et al.: A typical Y1 receptor regulates feeding behaviors: effects of a potent and selective Y1 antagonist, J-115814. Mol. Pharmacol. (2001) 59(3):501-515.
   PubMed Web of Science ®Google Scholar
• POINDEXTER GS, BRUCE MA, LEBOULLUEC KL et al.: Dihydropyridine neuropeptide Y Y1 receptor antagonists. Bioorg. Med. Chem. Lett. (2002) 12(3):379-382.
   PubMed Web of Science ®Google Scholar
• DANIELS AJ, GRIZZLE MK, WIARD RP et al.: Food intake inhibition and reduction in body weight gain in lean and obese rodents treated with GW438014A, a potent and selective NPY-Y5 receptor antagonist. Regul. Pept. (2002) 106(1-3):47-54.
   PubMed Web of Science ®Google Scholar
• POINDEXTER GS, BRUCE MA, BREITENBUCHER JG et al.: Dihydropyridine neuropeptide Y Y1 receptor antagonists 2. Bioorg. Med. Chem. Lett. (2004) 12(2):507-521.
   Web of Science ®Google Scholar
• FELETOU M, LEVENS NR: Neuropeptide Y2 receptor as drug targets for the central regulation of body weight. Curr. Opin. Investig. Drugs (2005) 6(10):1002-1011.
   PubMedGoogle Scholar
• BLOCK MH, BOYER S, BRAILSFORD W et al.: Discovery and optimization of a series of carbazole ureas as NPY5 antagonists for the treatment of obesity. J. Med. Chem. (2002) 45(16):3509-3523.
   PubMed Web of Science ®Google Scholar
• TURNBULL AV, ELLERSHAW L, MASTERS DJ et al.: Selective antagonism of the NPY5 receptor does not have a major effect on feeding in rats. Diabetes (2002) 51(8):2441-2449.
   PubMed Web of Science ®Google Scholar
• CLARCK DE, HIGGS C, WREN SP et al.: A virtual screening approach to finding novel and potent antagonists at the melanin-concentrating hormone-1 receptor. J. Med. Chem. (2004) 47(16):3962-3971.
   PubMed Web of Science ®Google Scholar
• BOROWSKY B, DURKIN MM, OGOZALEK K et al.: Antidepressant, anxiolytic and anorectic effects of a melanin-concentrating hormone-1 receptor antagonist. Nat. Med. (2002) 8(8):825-830.
   PubMed Web of Science ®Google Scholar
• MASHIKO S, ISHIHARA A, GOMORI A et al.: Antiobesity effects of a menanin concentrating hormone 1 receptor antagonist in diet-induced obese mice. Endocrinology (2005) 146(7):3080-3086.
   PubMed Web of Science ®Google Scholar
• SHEARMAN LP, CAMACHO RE, SLOAN STRIBLING D et al.: Chronic MCH-1 receptor modulation alters appetite, body weight and adiposity in rats. Eur. J. Pharmacol. (2003) 475(1-3):37-47.
   PubMed Web of Science ®Google Scholar
• KOWALSKI TJ, FARLEY C, COHEN-WILLIAMS ME et al.: Melanin-concentrating hormone-1 receptor antagonism decreases feeding by reducing meal size. Eur. J. Pharmacol. (2004) 497(1):41-47.
   PubMed Web of Science ®Google Scholar
• SOUERS AJ, GAO J, BRUNE M et al.: Identification of 2-(4-benzyloxyphenyl)-N-[1-(2-pyrrolidin-1-yl-ethyl)-1H-indazol-6y]acetamide, an oral efficacious melanin-concentrating hormone receptor 1 antagonist for the treatment of obesity. J. Med. Chem. (2005) 48(5):1318-1321.
   PubMed Web of Science ®Google Scholar
• PALANI A, SHAPIRO S, McBRIAR MD et al.: Biaryl ureas as potent and oral efficacious melanin concentrating hormone receptor 1 antagonists for the treatment of obesity. J. Med. Chem. (2005) 48(15):4746-4749.
   PubMed Web of Science ®Google Scholar
• BOEHM BO, LUSTIG RH: Use of somatostatin receptor ligands in obesity and diabetic complications. Best Pract. Res. Clin. Gastroenterol. (2002) 16(3):493-509.
   PubMed Web of Science ®Google Scholar
• GAMBINERI A, PATTON L, DE IASIO R et al.: Efficacy of octreotide-LAR in dieting women with abdominal obesity and polycystic ovary syndrome. J. Clin. Endocrinol. Metab. (2005) 90(7):3854-3862.
   PubMed Web of Science ®Google Scholar
• HAQQ AM, STADLER DD, ROSENFELD RG et al.: Circulating ghrelin levels are suppressed by meals and octreotide therapy in children with Pradder-Willi syndrome. J. Clin. Endocrinol. Metab. (2003) 88(8):3573-3576.
   PubMed Web of Science ®Google Scholar
• SILVA AP, BETHMANN K, RAULF F et al.: Regulation of ghrelin secretion by somatostatin analogues in rats. Eur. J. Endocrinol. (2005) 152(6):887-894.
   PubMed Web of Science ®Google Scholar
• KERSTEN S: Peroxisome proliferator activated receptors and obesity. Eur. J. Pharmacol. (2002) 440(2-3):223-234.
   PubMed Web of Science ®Google Scholar
• PETERS JM, LEE SS, LI W et al.: Growth, adipose, brain and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor δ. Mol. Cell. Biol. (2000) 20:5119-5128.
   PubMed Web of Science ®Google Scholar
• ROSENBERGER TA, HOVDA JT, PETERS JM: Targeted disruption of peroxisome proliferator-activated receptor δ results in distinct gender differences in mouse brain phospholipid and esterified fatty acid levels. Lipids (2002) 37:495-500.
   PubMed Web of Science ®Google Scholar
• MUSCAT GE, DRESSEL U: Cardiovascular disease and PPAR-δ: targeting the risk factors. Curr. Opin. Investig. Drugs (2005) 6(9):887-894.
   PubMedGoogle Scholar
• OLIVER WR Jr, SHENK JL, SNAITH MR et al.: A selective peroxisome proliferator-activated receptor-δ agonist promotes reverse cholesterol transport. Proc. Natl. Acad. Sci. USA (2001) 98:5306-5311.
   PubMed Web of Science ®Google Scholar
• MUOIO OM, McLEAN PS, LANG DB et al.: Fatty acid homeostasis and induction of lipid regulatory genes in skeletal muscles of peroxisome proliferator-activated receptor (PPAR) α knock-out mice. Evidence for compensatory regulation by PPAR δ. J. Biol. Chem. (2002) 277:26089-26097.
   PubMed Web of Science ®Google Scholar
• DRESSEL U, ALLEN TL, PIPPAL JB et al.: The peroxisome proliferator-activated receptor β/δ agonist, GW501516, regulates the expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells. Mol. Endocrinol. (2003) 17(12):2477-93.
   PubMed Web of Science ®Google Scholar
• MUKHERJEE R, HOENER PA, JOW L et al.: A selective peroxisome proliferator activated receptor-γ (PPAR-γ) modulator blocks adipocyte differentiation but stimulates glucose uptake in 3T3-L1 adipocytes. Mol. Endocrinol. (2000) 14(9):1425-1433.
   PubMed Web of Science ®Google Scholar
• ORTMANN S, KAMPE J, GOSSEL M et al.: The novel antiobesity HMR1426 reduces food intake withou affecting energy expenditure. Obes. Res. (2004) 12(8):1290-1297.
   PubMedGoogle Scholar
• BICKEL M, GOSSEL M, GEISEN K et al.: Analysis of the anorectic efficacy of HMR in rodents and its effects on gastric emptying in rats. Int. J. Obes. Relat. Metab. Disord. (2004) 28(2):211-221.
   PubMed Web of Science ®Google Scholar
• BAYS HE: Current and investigational antiobesity agents and obesity therapeutic treatment targets. Obes. Res. (2004) 12:1197-1211.
   PubMedGoogle Scholar
• SHAPIRA NA, GOLDSMITH TD, McELROY SL: Treatment of binge-eating disorder with topiramate: a clinical case series. J. Clin. Psychiatry (2000) 61(5):368-372.
   PubMed Web of Science ®Google Scholar
• McELROY SL, ARNOLD LM, SHAPIRA NA et al.: Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial. Am. J. Psychiatry (2003) 160(2):255-261 [Erratum in: Am. J. Psychiatry (2003) 160(3):612].
   PubMed Web of Science ®Google Scholar
• SMATHERS SA, WILSON JG, NIGRO MA: Topiramate effectiveness in Prader-Willi syndrome. Pediatr. Neurol. (2003) 28(2):130-133.
   PubMed Web of Science ®Google Scholar
• BRAY GA, HOLLANDER P, KLEIN S et al.: A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes. Res. (2003) 11(6):722-733.
   PubMedGoogle Scholar
• WILDING J, VAN GAAL L, RISSANEN A et al.: A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects. OBES-002 Study Group. Int. J. Obes. Relat. Metab. Disord. (2004) 28(11):1399-1410.
   PubMed Web of Science ®Google Scholar
• TONSTAD S, TYKARSKI A, WEISSGARTEN J et al.: Efficacy and safety of topiramate in the treatment of obese subjects with essential hypertension. Am. J. Cardiol. (2005) 96(2):243-251.
   PubMed Web of Science ®Google Scholar
• McELROY SL, SHAPIRA NA, ARNOLD LM et al.: Topiramate in the long-term treatment of binge-eating disorder associated with obesity. J. Clin. Psychiatry (2004) 65(11):1463-1469 [Erratum in: J. Clin. Psychiatry (2005) 66(1):138].
   PubMed Web of Science ®Google Scholar
• WINKELMAN JW: Treatment of nocturnal eating syndrome and sleep-related eating disorder with topiramate. Sleep Med. (2003) 4(3):243-246.
   PubMed Web of Science ®Google Scholar
• HARROLD JA, ELLIOTT JC, KING PJ et al.: Down-regulation of cannabinoid-1 (CB-1) receptors in specific extrahypothalamic regions of rats with dietary obesity: a role for endogenous cannabinoids in driving appetite for palatable food? Brain Res. (2002) 95(2):232-238.
   Google Scholar
• JAMSHIDI N, TAYLOR DA: Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats. Br. J. Pharmacol. (2001) 134:1151-1154.
   PubMed Web of Science ®Google Scholar
• HILLARD CT, CAMPBELL WB: Biochemistry and pharmacology of arachidonylethanolamine, a putative endogenous cannabinoid. J. Lipid Res. (1997) 38:2383-2398.
   PubMed Web of Science ®Google Scholar
• RAVINET TRILLOU C, DELGORGE C, MENET C et al.: CB1 cannabinoid knockout in mice leads to leaness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int. J. Obes. (2004) 28:640-648.
   Web of Science ®Google Scholar
• ARNONE M, MARUANI J, CHAPERON F et al.: Selective inhibition of sucrose and ethanol intake by SR141716, an antagonist of central cannabinoid (CB1) receptors. Psychopharmacology (1997) 132:104-106.
   PubMed Web of Science ®Google Scholar
• COLOMBO G, AGABIO R, DIAZ G et al.: Appetite suppression and weight loss after the cannabinoid antagonist SR141716. Life Sci. (1998) 63:L113-L117.
   Web of Science ®Google Scholar
• RAVINET TRILLOU C, ARNONE M, DELGORGE C et al.: Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2003) 284:R345-R353.
   PubMed Web of Science ®Google Scholar
• POIRIER B, BIDOUARD J-P, CADROUVELE C et al.: The anti-obesity effect of rimonabant is associated with an improved serum lipid profile. Diabetes Obes. Metab. (2005) 7:65-72.
   PubMed Web of Science ®Google Scholar
• DIMARZO V, GOPARAJU SK, WANG L et al.: Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature (2001) 410:824-825.
   Google Scholar
• BANSAID M, GARY-BOBO M, ESCLANGON A et al.: The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipose cells. Mol. Pharmacol. (2003) 63:908-914.
   PubMed Web of Science ®Google Scholar
• COTA D, MARSICANO G, TSCHÖP M et al.: The endogenous cannabinoid system affects energy balance via central orexigenic and peripheral lipogenesis. J. Clin. Invest.. (2003) 112:423-431.
   PubMed Web of Science ®Google Scholar
• LIU YL, CONNOLEY IP, WILSON CA, STOCK MJ: Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lepob/Lepob mice. Int. J. Obes. (2005) 29:183-187.
   PubMed Web of Science ®Google Scholar
• OSEI-HYIAMAN D, DEPETRILLO M, PACHER et al.: Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J. Clin. Invest. (2005) 115:1298-1305.
   PubMed Web of Science ®Google Scholar
• BLACK SC: Cannabinoid receptor antagonists and obesity. Curr. Opin. Investig. Drugs (2004) 5(4):389-394.
   PubMedGoogle Scholar
• PI-SUNYER X: Clinical design of the studies of weight reduction and metabolic effects with rimonabant: the RIO (Rimonabant in Obesity) program. Annual Meeting of the North American Association for the Study of Obesity, Las Vegas, USA (14 – 18 November 2004):108-OR (Abstract).
   Google Scholar
• VAN GAAL LF, RISSANEN AM, SCHEEN AJ et al.: Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. RIO-Europe Study Group. Lancet (2005) 365(9468):1389-1397 [Erratum in: Lancet (2005) 366(9483):370].
   PubMed Web of Science ®Google Scholar
• PI-SUNYER FX: Effect of rimonabant on weight reduction and weight mainteinance: RIO-North America (RIO-NA) Trial. Circulation (2005) 111(13):1727 (Abstract).
   Google Scholar
• DESPRÉS J-P, GOLAY A, SJÖSTRÖM L: Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. Rimonabant in Obesity–Lipids Study Group. N. Engl. J. Med. (2005) 353(20):2121-2134.
   PubMed Web of Science ®Google Scholar
• FINER N: Weight reducing and metabolic effects of rimonabant in overweight/obese patients: the results from the RIO-LIPIDS Trial. 1st Regional Congress of the International Association for the Study of Obesity, Sun City, South Africa (28 – 31 October 2004).
   Google Scholar
• DESPRÉS J-P: Significant improvement in the quality of life of overweight/obese dyslipidemic patients treated with rimonabant: Results from the RIO-LIPIDS Trial [abstract 231-P]. Annual Meeting of the North American Association for the Study of Obesity, Las Vegas, USA (14 – 18 November 2004).
   Google Scholar
• PAGOTTO U, PASQUALI R: Fighting obesity and associated risk factors by antagonising cannabinoid Type 1 receptors. Lancet (2005) 365:1363-1364.
   PubMed Web of Science ®Google Scholar
• RINALDI-CARMONA M, BARTH F, CONGY C et al.: SR147778 [5-(4-bromophenyl)- 1-(2,4-dichlorophenyl)-4-ethyl-N- (1-piperidinyl)-1H-pyrazole-3-carbox amide], a new potent and selective antagonist of the CB1 cannabinoid receptor: biochemical and pharmacological characterization. J. Pharmacol. Exp. Ther. (2004) 310(3):905-914.
   PubMed Web of Science ®Google Scholar
• DOGGRELL SA: Will the new CB1 cannabinoid receptor antagonist SR-147778 have advantages over rimonabant? Expert Opin. Investig. Drugs (2005) 14(3):339-342.
   PubMed Web of Science ®Google Scholar